Replies to post #106824 on Savvy Trades and Investments

[researcher59]

CVS deservedly getting hit, but I don't think many analysts saw Blue Shield of California dropping them .... it's out of the blue ! Presumably some analyst downgrades will be forthcoming, but whether Blue Shield will really be saving money by parceling out the pharmacy process remains to be seen. Sounds like "California Math" to me. jmho

[jtomm]

PRPH ($5.67) - Any interest at these levels as these guys try to move on from covid testing? They now describe themselves as "a next-generation biotech, genomics and diagnostics company." Which, frankly, sounds a little "kitchen sinky" to me. Ceo has had a good history, is generally optimistic, and has pivoted successfully before. But I'm leery that he might be over his head in biotech and genomics. He keeps talking about big things from genomics testing, but dates keep getting pushed back and not seeing much yet.

I like where the stock price has come down to, and if I believed the genomics testing was just a matter of time (as the CEO does) I'd be tempted. But I'm concerned that not only is he over his skis, but also these things might take much more govt approval time and testing than he realizes.